Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators.
Patients who have drug-resistant tuberculosis have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine.
A new study has identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small-cell lung cancer treated with a combination of immunotherapy and low-dose radiation.
Weill Cornell researchers find inflammatory bowel disease drug works by modulating the activity of a group of gut bacteria that are more abundant in patients who respond to the drug.
An experimental mRNA vaccine against human cytomegalovirus, a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any vaccine candidate, according to a study by Weill Cornell Medicine investigators.
Cornell’s participation in the U.S. Commerce Department initiative will help advance development and deployment of safe and trustworthy artificial intelligence technology.
A multicenter, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atrial cardiopathy, according to new research.
Alessio Accardi, professor of physiology and biophysics in anesthesiology at Weill Cornell Medicine, has been awarded a five-year, $2.7 million grant for fundamental research on cell membrane proteins that have critical roles in biology and are involved in numerous human diseases.
